Advertising

CVE:COV

2.98
0.06 (1.97%) 1d
0
Showing 1 to 15 of 16 entries
PAST TOP PICK
(A Top Pick Aug 08/18, Down 78%) They had a $100 million contract from the Middle East, but the revenue in the deal has been delayed. COV had huge promise and now it's Show Me The Money. The revenue delay is hurting them. Also, they had a recent stock issuance. But insiders still own a big chunk of this.
medical services
WEAK BUY
Bandages and dressings / wound care. They made a few miss-steps recently. An overseas issue has been addressed. They signed some agreements overseas and the revenue is not yet coming in. Even if the contracts don't generate cash flows, it is already in the stock, but if money comes in there could be upside from it. They are working in other areas as well. He likes the trade-off
medical services
WATCH
He does not own this bio-tech company. He just does not follow it enough currently to comment. Management has changed so he hopes it will improve things.
medical services
WATCH
They make bandage products. They are developing new products all the time. A big contract in the Middle East is creating a chunky quarter result and raising concerns about Saudi Arabia geopolitics. Over the next six months revenues should increase so you want to watch for a while.
medical services
RISKY BUY
He likes their potential, especially with a $100 million project in the Middle East (although Canada's relation with Saudi Arabia is strained). They make wound bandages and compete against companies like Johnson&Johnson. This should be a good year. They are debt free and are expanding their business in the US. He would endorse the management team. It is a speculative buy until they can bring forward more contracts to monetize their cash flow.
medical services
COMMENT
Essentially health care dressing, bandages and things like that. They have a big entrance into the market when they won a big contract in Saudi Arabia but now there are concerns with all the problems with that country. They have a foot on the US side now as well. Revenue is very good. It is high risk as it is a small name.
medical services
BUY
He considers it a quality company and worth owning. He likes the balance sheet and the product. The management company has sold companies before. Put it away and don’t look at it on a daily basis.
medical services
TOP PICK

This company makes wound dressings for medical devices and just won a $100 million contract overseas. Earnings growth is going to massively accelerate with the new contract. He wants to see them get another contract and they have good potential for growth in Europe. Yield 0%.

medical services
BUY

They make medical supplies, signed a large contract recently and are doing well. They compete successfully with companies like 3M overseas. The stock is not very liquid because there is one very large owner. It has risen recently, but if you own it, you should hang onto it. They surprise people with good news, which shows up in the stock price.

medical services
COMMENT

It is not a well known name at all. It is medical products. One investor owns close to a half of it. They are gaining market share. He is guessing they are a takeout play at some point.

medical services
WATCH

It is quite illiquid. They are a medical supply company that is beating out 3M on a number of contracts. It has a lot of promise. He is looking into it and thinks it will be worth buying.

medical services
COMMENT

Supply every type of thing that a company would need in a hospital such as gowns, etc. These types of businesses tend to be very stable

medical services
BUY
Has done tremendously well. They focus on wound care products, and coatings for products. The company has tremendous potential, they signed a deal with a large British company. Great opportunity, going to do well going forward.
medical services
BUY
An interesting little company. Have a wound care product. Also have intellectual property around coatings, basically silver-based, that prevents infection. As they get more partnerships on the coatings, the stock will move up.
medical services
BUY
A fantastic success story. Have technology in the wound dressing area. There are also rumours of a big deal coming their way. Fantastic management.
medical services
Showing 1 to 15 of 16 entries

Covalon Technologies(COV-X) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Covalon Technologies is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Covalon Technologies(COV-X) Frequently Asked Questions

What is Covalon Technologies stock symbol?

Covalon Technologies is a Canadian stock, trading under the symbol COV-X on the TSX Venture Exchange (COV-CV). It is usually referred to as TSXV:COV or COV-X

Is Covalon Technologies a buy or a sell?

In the last year, there was no coverage of Covalon Technologies published on Stockchase.

Is Covalon Technologies a good investment or a top pick?

Covalon Technologies was recommended as a Top Pick by on . Read the latest stock experts ratings for Covalon Technologies.

Why is Covalon Technologies stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Covalon Technologies worth watching?

0 stock analysts on Stockchase covered Covalon Technologies In the last year. It is a trending stock that is worth watching.

What is Covalon Technologies stock price?

On 2021-09-24, Covalon Technologies (COV-X) stock closed at a price of $2.98.